Naphthonone is an antitussive agent.

Vicriviroc or SCH 417690 is a potent and selective antagonist of the CCR5 receptor. vicriviroc binds specifically to the CCR5 receptor and prevents infection of target cells by CCR5-tropic HIV-1 isolates. In antiviral assays, vicriviroc showed potent, broad-spectrum activity against genetically diverse and drug-resistant HIV-1 isolates and was consistently more active than SCH-C in inhibiting viral replication. This compound demonstrated synergistic anti-HIV activity in combination with drugs from all other classes of approved antiretrovirals. Competition binding assays revealed that vicriviroc binds with higher affinity to CCR5 than SCH-C. Functional assays, including inhibition of calcium flux, guanosine 5'-[35S]triphosphate exchange, and chemotaxis, confirmed that vicriviroc acts as a receptor antagonist by inhibiting signaling of CCR5 by chemokines. Finally, vicriviroc demonstrated diminished affinity for the human ether a-go-go related gene transcript ion channel compared to SCH-C, suggesting a reduced potential for cardiac effects. Vicriviroc represented a promising new candidate for the treatment of HIV-1 infection. Vicriviroc for HIV treatment was previously in Phase III studies but has since been discontinued.

LAPRAFYLLINE is a xanthine derivative with bronchodilating effect. It might exert its action by inhibiting cAMP phosphodiesterase.

LAMTIDINE is an irreversible and specific gastric histamine H2-receptor antagonist.

KETOCAINE is a local anesthetic.

Talotrexin (also known as PT-523) was developed as a nonpolyglutamatable antifolate drug for the treatment of various types of tumors. It is known that antifolates are a class of cytotoxic or antineoplastic agents, which inhibit or prevent the maturation and proliferation of malignant cells. Talotrexin was studied in clinical trials for the treatment of brain and central nervous system tumors, leukemia, lymphoma, unspecified childhood solid tumor. However, this study was withdrawn because of toxicity. In addition, was studied in phase I/II multicenter clinical trial in patients with non-small-cell Lung carcinoma, this study was also withdrawn. The withdrawal was related to incidences of dose-limiting mucositis and myelosuppression. However, on May 22, 2006, was announced that the U.S. Food and Drug Administration has granted orphan drug designation for talotrexin in patients with acute lymphoblastic leukemia (ALL).

Sotirimod is designed to treat actinic keratosis and other conditions and is a follow-up of Aldara (active substance: imiquimod). Sotirimod and imiquimod are immunomodulatory drugs that activate the body's immune system to combat skin changes such as actinic keratosis. Sotirimod is immunostimulants and Toll-like receptor 7 agonist. Sotirimod was originally developed by 3M Pharmaceuticals, then licensed to Meda in Europe for the treatment of actinic keratosis in 2007. Sotirimod had been in phase III development for the treatment of actinic keratosis. However, there is no recent development report for this study.

Butoxylate is organic compound with significant analgesic or mydriatic activity after s.c. injection in mice and rats

Tipetropium is atropine derivative. It is the adrenoceptor agonist. Tipetropium is bronchospasmolytic agent. It was used as anti-asthmatic drug.

Beloxepin (or ADL6906), a novel dual norepinephrine reuptake inhibitor and serotonin receptor antagonist, was investigated for the treatment of the pain and Major depressive disorder, but these studies were discontinued.